21.04.2017 19:18
Bewerten
(0)

ASIT biotech to publish its annual financial report on Tuesday, April 25, 2017

DRUCKEN

Regulatory News:

ASIT biotech (Paris:ASIT) (BSE:ASIT) (ASIT - BE0974289218), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, informs the financial community that, due to administrative reasons, the publication of its annual financial report (regulated information) has been pushed back from April 21, 2017 to April 25, 2017.

***

About ASIT biotech

ASIT Biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+TM technology platform, ASIT biotech is currently the only developer of AIT product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline entails two novel ASIT+™ product candidates targeting respiratory allergy with the highest prevalence (i.e. grass pollen: gp-ASIT+TM and house dust mite: hdm-ASIT+TM), that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

ASIT biotech has a headcount of 22 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.

Further information can be found at www.asitbiotech.com.

Forward-looking statements

All statements in this announcement that do not relate to historical facts and events are "forward-looking statements”. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes,” "estimates,” "anticipates,” "expects,” "intends,” "may,” "will,” "plans,” "continue,” "ongoing,” "potential,” "predict,” "project,” "target,” "seek” or "should” or, in each case, their negative or other variations or comparable terminology or by discussions of strategies, plans, objectives, targets, goals, future events or intentions. Forward-looking statements include statements regarding the Company’s intentions, beliefs or current expectations. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. Given these risks and uncertainties, you should not rely on forward-looking statements as a prediction of actual results. Any forward-looking statements are made only as of the date of this announcement and, without prejudice to the Company’s obligations under applicable law in relation to disclosure and ongoing information, the Company does not intend, and does not assume any obligation, to update the forward-looking statements set forth in this announcement.

Legal notice

This announcement does not constitute, or form part of, an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for shares of ASIT biotech SA (the "Company” and the "Shares”). Any purchase of, subscription for or application for, Shares to be issued in connection with the intended offering should only be made on the basis of information contained in the prospectus and any supplements thereto, as the case may be. This announcement does not constitute a prospectus and the information contained herein is for information purposes only and does not purport to be full or complete. Investors should not subscribe for any Shares except on the basis of the information contained in the prospectus that the Company expects to publish after its approval by the Belgian Financial Services and Markets Authority, and which can then be obtained at the Company’s registered office and on www.asitbiotech.com.

This announcement is not for distribution, directly or indirectly, in or into the United States or to any U.S. person within the meaning of the U.S. Securities Act of 1933, as amended (the "Securities Act”). The Shares have not been and will not be registered under the Securities Act and may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act. The Company has not registered, and does not intend to register, any portion of the intended offering of Shares in the United States, and does not intend to conduct a public offering of Shares in the United States.

This announcement and the information contained herein are not for publication, distribution or release in or into the United States, Australia, Canada, Japan or any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

The Company is responsible for the information contained in this press release.

Nachrichten zu ASIT Biotech S.A.

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu ASIT Biotech S.A.

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
Keine Analysen gefunden.
mehr Analysen

Heute 18 Uhr: Investieren in Künstliche Intelligenz

Wer als Anleger frühzeitig in Trends wie Künstliche Intelligenz investiert, kann kräftig profitieren. Heute Abend wird Silicon Valley-Experte Thomas Rappold gleich drei solcher Megatrends ausführlich vorstellen.
Hier kostenlos zum Webinar anmelden!

Meistgelesene ASIT Biotech News

Keine Nachrichten gefunden.
Weitere ASIT Biotech News
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Bechtle - Der Favorit im IT-Segment!

Ein breit aufgestelltes, gut diversifiziertes Produkt- und Serviceangebot, eine solide Finanzbasis und ein gutes Gespür für chancenreiche Trends und wachstumsstarke Marktsegmente - diese Mischung ist das Erfolgsgeheimnis von Bechtle. Lesen Sie im aktuellen Anlegermagazin die ganze Story über Bechtle.
Kostenfrei registrieren und dabei sein!

ASIT Biotech Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

DAX fester -- Asiens Börsen legen zu -- Kurseinbruch: Bitcoin unter 12.000 Dollar -- US-Klage wirft Deutscher Bank Manipulation von kanadischem Zins vor -- Covestro, HUGO BOSS im Fokus

Nordex drehen nach gutem Lauf - Wettbewerber aussichtsreicher. Hedgefonds-Legende Novogratz plant eigene Bitcoin-Bank. Siemens Healthineers strebt hohe Dividendenausschüttung an. Allianz-Chef erteilt Lebensversicherungen mit Garantiezins Absage. Experte: Goldpreis könnte 2018 positiv überraschen.

Top-Rankings

KW 2: Analysten-Tops der Woche
Diese Aktien stehen auf den Kauflisten der Experten
Die besten Airlines der Welt 2017
Welche Fluggesellschaft macht das Rennen?
Das Wachstum der Schulden in verschiedenen Regionen
Welche Region konnte ihren Schuldenberg am meisten verkleinern?

Umfrage

Wünschen Sie sich, dass sich Union und SPD erneut auf eine große Koalition (GroKo) einigen?

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Steinhoff International N.V.A14XB9
Deutsche Bank AG514000
Volkswagen (VW) AG Vz.766403
Daimler AG710000
Nordex AGA0D655
EVOTEC AG566480
CommerzbankCBK100
Deutsche Telekom AG555750
ProSiebenSat.1 Media SEPSM777
Amazon906866
BYD Co. Ltd.A0M4W9
Lufthansa AG823212
Apple Inc.865985
Siemens AG723610
Allianz840400